CanSino BiologicsLaunches Phase III Trial for DTcP Vaccine in Infants and Young Children
CanSino Biologics Inc. a leading China-based vaccines specialist (HKG: 6185), has announced the initiation of...
Hunan HSA Implements Direct BMI Fund Payments for VBP-Winning Drugs and Consumables
The Hunan Healthcare Security Administration (HSA) bureau has released a notice stating that effective from...
SAMR and Nine Ministries Tighten Regulations on Forums and Conferences in China
The State Administration for Market Regulation (SAMR) of China, in conjunction with nine other ministries,...
Cutia Therapeutics’ CU-10201 Enters Priority Review for Acne Treatment in China
Dermatology therapy developer Cutia Therapeutics (HKG: 2487) has announced that its CU-10201, a 4% minocycline...
Huadong Medicine Secures Exclusive Rights to Arcutis’ Daxas in Greater China and South-East Asia
Huadong Medicine Co., Ltd (SHE: 000963) has announced a significant licensing agreement with Arcutis (NASDAQ:...
Medtronic Partners with APMG to Advance Orthopedic Treatment Services in China
US-based Medtronic Inc., (NYSE: MDT) has entered into a partnership with China’s private healthcare group...
Everest Medicines and Shanghai Pharmaceuticals Deepen Partnership for Drug Distribution in China
China-based Everest Medicines (HKG: 1952) has announced a strategic partnership with Shanghai Pharmaceuticals marking a...
NMPA Greenlights Oricell Therapeutics’ OriCAR-017 for Clinical Trials in Multiple Myeloma
The National Medical Products Administration (NMPA) has indicated on its website that Oricell Therapeutics Co.,...
Beijing Balance Medical Receives Approval for Innovative Expandable Artificial Heart Valve in China
Beijing Balance Medical Technology Co., Ltd (SHA: 688198), a leading medical technology company in China,...
WuXi Biologics and Boostimmune Forge Exclusive R&D Partnership
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a...
Antengene Corp. Secures Licensing Deal with Hansoh Pharmaceutical for Xpovio in China
China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced a significant licensing agreement with...
Novo Nordisk’s H1 2023 Financials Show 30% YOY Growth Driven by GLP-1 Drugs and Obesity Sales
Denmark-based pharmaceutical company Novo Nordisk A/S (NYSE: NVO) has announced its financial results for the...
Pfizer Faces Whistleblower Lawsuit Over Alleged FCPA Violations in China
A former employee of Pfizer Inc., (NYSE: PFE), Frank Han, has filed a civil lawsuit...
Organon Reports Q2 2023 Revenue Growth, Driven by Women’s Health and Biosimilars
US-based Organon (NYSE: OGN) has reported its financial results for the second quarter of 2023,...
Regeneron Pharmaceuticals Acquires Decibel Therapeutics for Hearing Loss Gene Therapies
US-based biopharmaceutical company Regeneron Pharmaceuticals Inc., (NASDAQ: REGN) has announced the acquisition of fellow US...
Denali Therapeutics and Takeda Halt Development of Alzheimer’s Drug Candidate TAK-920/DNL919
US-based biopharmaceutical company Denali Therapeutics Inc., (NASDAQ: DNLI) has announced in its Q2 2023 financial...
Poseida Therapeutics Secures $50 Million Investment from Astellas for Cell and Gene Therapy
US-based cell and gene therapy developer Poseida Therapeutics, Inc. (NASDAQ: PSTX) has announced a significant...
Lee’s Pharmaceutical’s Subsidiary Completes Phase III Study for Myopia Treatment NVK002
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced...
Eyebright Medical Technology’s Intraocular Lenses Earn Fast-Track Status in China
Beijing-based Eyebright Medical Technology Co., Ltd (SHE: 688050) has announced that its “intraocular lenses with...
Neurophth Biotechnology Secures RMB700 Million in Series C+ Financing for Gene Therapy Development
China-based gene therapy specialist Neurophth Biotechnology Ltd has reportedly secured close to RMB700 million in...